however, the labeling for sitagliptin recommends appropriate monitoring and does not suggest dosage adjustments to either sitagliptin or digoxin
Back Mller, TD, Blher, M, Tschp, M, DiMarchi, iRD (2022) 'Anti-obesity drug discovery: advances and challenges', Nature Review Drug Discovery , 21, 201-23
top of page Shop the GLP-1 Products Collection the GLP-1 Newsroom Blog & News Page GLP-1 Newsroom is your go-to source for breaking news, expert updates, trends, products, and real-world insights on everything related to GLP-1 medications, journeys, and diets
Women have reported significant reductions in body weight and visceral fat, along with improvements in key metabolic markers
Imaging and biomarker endpoints The sharpest biomarker lesson from this literature comes from a negative trial